Trial reportScientific reports2026
Effects of trehalose supplementation on bone healing, physical function, and pain in patients with pertrochanteric fractures: a randomized controlled trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pertrochanteric fractures are common injuries associated with significant morbidity and delayed healing. Trehalose, a naturally occurring disaccharide with cytoprotective properties, has shown promise in preclinical fracture models. This randomized controlled trial evaluated the effects of trehalose supplementation on radiographic healing, hip function, and pain in patients with pertrochanteric fractures. This double-blind, placebo-controlled trial enrolled 64 patients (aged 18-60 years) with surgically treated pertrochanteric fractures at Taleghani Hospital, Tehran, Iran. Participants were randomly assigned to receive either trehalose (3.3 g/day) or placebo (sucrose) for 12 weeks. The co-primary outcomes were radiographic healing assessed by the Radiographic Union Score for Hip (RUSH) and physical function assessed by the Harris Hip Score (HHS). Secondary outcome was pain intensity assessed by the Visual Analog Scale (VAS). Assessments were conducted at baseline and weeks 2, 4, and 12. Fifty-seven participants completed the study (trehalose n = 28; placebo n = 29). The trehalose group showed significantly higher RUSH scores at week 12 compared with placebo (mean difference 2.09 points; 95% CI 0.45 to 3.72; p = 0.014), with significant group effect (p = 0.050) and group-by-time interaction (p = 0.021). Hip function improved more in the trehalose group, with significantly higher HHS at week 12 (mean difference 8.55 points; 95% CI 3.97 to 13.13; p < 0.001). Pain decreased substantially in both groups with no significant between-group difference.Trehalose supplementation improved radiographic healing and hip function in patients with pertrochanteric fractures. No serious adverse events were reported, but adverse events were not systematically monitored. Larger trials with longer follow-up and structured safety monitoring are needed to confirm these results and evaluate late complications.Trial registration: Iranian Registry of Clinical Trials. IRCT20240605062013N1. URL of the trial registry record https://irct.behdasht.gov.ir/trial/77212 , Registration date 16 June 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.